Research programme: protein therapeutics - Acceleron

Drug Profile

Research programme: protein therapeutics - Acceleron

Alternative Names: ACE 1334; ACE-1332; ACE-2395; ACE-2536; ACE-2798

Latest Information Update: 23 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acceleron Pharma
  • Class Antifibrotics; Antineoplastics; Proteins
  • Mechanism of Action TGF-beta superfamily protein-modulators; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Fibrosis; Lung disorders; Myelofibrosis

Most Recent Events

  • 19 Sep 2017 Preclinical trials in Lung disorders in USA (unspecified route)
  • 17 Mar 2016 Preclinical trials in Cancer in USA (unspecified route)
  • 17 Mar 2016 Preclinical trials in Fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top